Wordt geladen...
HOSPITAL INITIATED INJECTABLE OPIOID AGONIST THERAPY FOR THE TREATMENT OF SEVERE OPIOID USE DISORDER
BACKGROUND: Across North America, there is an unprecedented opioid overdose epidemic. Approximately 15% of individuals with severe opioid use disorder (OUD) do not benefit from opioid agonist therapy (OAT) such as buprenorphine/naloxone or methadone and are considered treatment refractory. Of those...
Bewaard in:
| Gepubliceerd in: | J Addict Med |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7927900/ https://ncbi.nlm.nih.gov/pubmed/32769776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/ADM.0000000000000713 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|